Out of an abundance of caution, because it is a new treatment modality, I got a retina scan done to look for any evidence of maculopathy. There was none - the opthalmologists comment was “it looks very young and healthy” (I just turned 56).
My lifetime burden of PPS, after three courses of iPPS, is about 6 g, far less than the 2.2 kg in this study. There should be no concern about retinal maculopathy.
research reports and media, page-3755
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 20.0¢ | $39.81K | 198.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 200204 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 157579 | 5 |
View Market Depth
| Last trade - 10.43am 09/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |